Search

everythinglearnresearchcommunity

for

Search:↓

The user shared their personal experience with hair loss, hormone imbalances, and treatments including testosterone boosters, natural estrogen blockers, and DHEA. They suggest that low-dose finasteride and natural hormone therapy could reduce hair loss with fewer side effects.

The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.

An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

Significant hair growth was achieved using Minoxidil 5% and dermarolling twice a week, with suggestions to add finasteride for maintenance. There is debate on when to apply Minoxidil after dermarolling to avoid irritation.

Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.

Thinning scissors can worsen the appearance of already thin hair. Some recommend being clear with barbers and using Minoxidil for hair loss.

Finasteride can aid hair regrowth but may cause side effects like depression and sexual dysfunction. Users discuss experiences with finasteride, minoxidil, and RU58841, highlighting varied responses and the importance of informed treatment choices.

The user is trying to maximize minoxidil's effectiveness by applying it for only one hour to avoid spreading it to furniture and pets, especially cats. They experience side effects when combining minoxidil with dermarolling and are considering alternatives like oral minoxidil or microneedling.

A user who has been using Pyrilutamide for 19 days, experiencing some hair thickening in the right temple and crown area but also having ball ache after microneedling; other users offer advice, caution and skepticism as to whether results can be seen in such a short time.

People who had posted about using pyrilutamide for hair loss, but did not return with an update; the potential side effects of pyrilutamide, RU58841 and other treatments such as minoxidil and finasteride were discussed.

The conversation provides a six-step guide on how to get a prescription for oral minoxidil (OM) for hair loss by finding a supportive dermatologist, even if they are not local, and preparing a case for its use during a virtual consultation. The guide emphasizes the importance of research, insurance considerations, and the potential for initial hair shedding with OM treatment.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.